nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—HRH1—atherosclerosis	0.511	1	CbGaD
Mianserin—CYP2B6—Simvastatin—atherosclerosis	0.0447	0.217	CbGbCtD
Mianserin—CYP2D6—Niacin—atherosclerosis	0.0273	0.133	CbGbCtD
Mianserin—CYP2D6—Simvastatin—atherosclerosis	0.0216	0.105	CbGbCtD
Mianserin—CYP2D6—Pravastatin—atherosclerosis	0.0211	0.103	CbGbCtD
Mianserin—CYP2D6—Lovastatin—atherosclerosis	0.0211	0.103	CbGbCtD
Mianserin—CYP3A4—Rosuvastatin—atherosclerosis	0.0148	0.0717	CbGbCtD
Mianserin—CYP3A4—Ezetimibe—atherosclerosis	0.0148	0.0717	CbGbCtD
Mianserin—CYP3A4—Simvastatin—atherosclerosis	0.0137	0.0666	CbGbCtD
Mianserin—CYP3A4—Lovastatin—atherosclerosis	0.0134	0.0652	CbGbCtD
Mianserin—CYP3A4—Pravastatin—atherosclerosis	0.0134	0.0652	CbGbCtD
Mianserin—HTR2A—arteriole—atherosclerosis	0.00291	0.116	CbGeAlD
Mianserin—HTR7—vein—atherosclerosis	0.00278	0.111	CbGeAlD
Mianserin—Blood disorder—Rosuvastatin—atherosclerosis	0.00242	0.0215	CcSEcCtD
Mianserin—Hepatic enzyme increased—Rosuvastatin—atherosclerosis	0.00213	0.019	CcSEcCtD
Mianserin—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00181	0.0161	CcSEcCtD
Mianserin—HTR2A—vein—atherosclerosis	0.00173	0.0694	CbGeAlD
Mianserin—Gynaecomastia—Lovastatin—atherosclerosis	0.00153	0.0136	CcSEcCtD
Mianserin—Gynaecomastia—Simvastatin—atherosclerosis	0.00143	0.0127	CcSEcCtD
Mianserin—HTR1D—artery—atherosclerosis	0.00142	0.0569	CbGeAlD
Mianserin—Hepatic function abnormal—Lovastatin—atherosclerosis	0.00142	0.0126	CcSEcCtD
Mianserin—Hepatic function abnormal—Simvastatin—atherosclerosis	0.00133	0.0118	CcSEcCtD
Mianserin—Breast disorder—Rosuvastatin—atherosclerosis	0.00132	0.0118	CcSEcCtD
Mianserin—Gynaecomastia—Pravastatin—atherosclerosis	0.00129	0.0115	CcSEcCtD
Mianserin—Arthritis—Lovastatin—atherosclerosis	0.00128	0.0114	CcSEcCtD
Mianserin—Arthritis—Ezetimibe—atherosclerosis	0.00125	0.0111	CcSEcCtD
Mianserin—Hepatic function abnormal—Niacin—atherosclerosis	0.00122	0.0109	CcSEcCtD
Mianserin—Hepatic function abnormal—Pravastatin—atherosclerosis	0.0012	0.0107	CcSEcCtD
Mianserin—Arthritis—Simvastatin—atherosclerosis	0.00119	0.0106	CcSEcCtD
Mianserin—HTR2A—hindlimb—atherosclerosis	0.00115	0.0461	CbGeAlD
Mianserin—HTR7—artery—atherosclerosis	0.00113	0.0454	CbGeAlD
Mianserin—HTR1D—blood vessel—atherosclerosis	0.00111	0.0444	CbGeAlD
Mianserin—Jaundice—Rosuvastatin—atherosclerosis	0.0011	0.00979	CcSEcCtD
Mianserin—Breast disorder—Ezetimibe—atherosclerosis	0.0011	0.00979	CcSEcCtD
Mianserin—Arthritis—Niacin—atherosclerosis	0.0011	0.00976	CcSEcCtD
Mianserin—Arthritis—Pravastatin—atherosclerosis	0.00108	0.00961	CcSEcCtD
Mianserin—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00107	0.0095	CcSEcCtD
Mianserin—Diplopia—Pravastatin—atherosclerosis	0.00105	0.00934	CcSEcCtD
Mianserin—Hepatitis—Rosuvastatin—atherosclerosis	0.00101	0.00902	CcSEcCtD
Mianserin—Phenindamine—HRH1—atherosclerosis	0.00101	0.138	CrCbGaD
Mianserin—HTR2A—appendage—atherosclerosis	0.000988	0.0396	CbGeAlD
Mianserin—Erectile dysfunction—Lovastatin—atherosclerosis	0.000988	0.00879	CcSEcCtD
Mianserin—Erectile dysfunction—Ezetimibe—atherosclerosis	0.000969	0.00863	CcSEcCtD
Mianserin—HTR7—endothelium—atherosclerosis	0.000957	0.0383	CbGeAlD
Mianserin—Erectile dysfunction—Simvastatin—atherosclerosis	0.000924	0.00823	CcSEcCtD
Mianserin—Jaundice—Ezetimibe—atherosclerosis	0.000915	0.00814	CcSEcCtD
Mianserin—Mental disorder—Rosuvastatin—atherosclerosis	0.000888	0.0079	CcSEcCtD
Mianserin—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000887	0.0079	CcSEcCtD
Mianserin—HTR7—blood vessel—atherosclerosis	0.000882	0.0353	CbGeAlD
Mianserin—Jaundice—Simvastatin—atherosclerosis	0.000872	0.00776	CcSEcCtD
Mianserin—Hepatitis—Lovastatin—atherosclerosis	0.000859	0.00764	CcSEcCtD
Mianserin—Erectile dysfunction—Niacin—atherosclerosis	0.000849	0.00755	CcSEcCtD
Mianserin—Hepatitis—Ezetimibe—atherosclerosis	0.000842	0.0075	CcSEcCtD
Mianserin—Erectile dysfunction—Pravastatin—atherosclerosis	0.000836	0.00744	CcSEcCtD
Mianserin—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000828	0.00737	CcSEcCtD
Mianserin—Weight increased—Pravastatin—atherosclerosis	0.000826	0.00735	CcSEcCtD
Mianserin—Hepatitis—Simvastatin—atherosclerosis	0.000803	0.00715	CcSEcCtD
Mianserin—Jaundice—Niacin—atherosclerosis	0.000801	0.00713	CcSEcCtD
Mianserin—Jaundice—Pravastatin—atherosclerosis	0.000789	0.00702	CcSEcCtD
Mianserin—Azatadine—HRH1—atherosclerosis	0.000786	0.108	CrCbGaD
Mianserin—Chlorcyclizine—HRH1—atherosclerosis	0.000775	0.106	CrCbGaD
Mianserin—HRH2—cardiovascular system—atherosclerosis	0.000774	0.031	CbGeAlD
Mianserin—Angiopathy—Ezetimibe—atherosclerosis	0.000764	0.0068	CcSEcCtD
Mianserin—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000759	0.00676	CcSEcCtD
Mianserin—Myalgia—Rosuvastatin—atherosclerosis	0.000751	0.00668	CcSEcCtD
Mianserin—Arthralgia—Rosuvastatin—atherosclerosis	0.000751	0.00668	CcSEcCtD
Mianserin—Mental disorder—Ezetimibe—atherosclerosis	0.000738	0.00657	CcSEcCtD
Mianserin—Hepatitis—Niacin—atherosclerosis	0.000738	0.00656	CcSEcCtD
Mianserin—Hepatitis—Pravastatin—atherosclerosis	0.000726	0.00646	CcSEcCtD
Mianserin—Confusional state—Rosuvastatin—atherosclerosis	0.000726	0.00646	CcSEcCtD
Mianserin—HTR2A—artery—atherosclerosis	0.000706	0.0283	CbGeAlD
Mianserin—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000706	0.00628	CcSEcCtD
Mianserin—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000705	0.00627	CcSEcCtD
Mianserin—Mental disorder—Simvastatin—atherosclerosis	0.000704	0.00626	CcSEcCtD
Mianserin—Tremor—Lovastatin—atherosclerosis	0.0007	0.00623	CcSEcCtD
Mianserin—Eye disorder—Niacin—atherosclerosis	0.000689	0.00613	CcSEcCtD
Mianserin—Tinnitus—Niacin—atherosclerosis	0.000688	0.00612	CcSEcCtD
Mianserin—Methdilazine—HRH1—atherosclerosis	0.000682	0.0935	CrCbGaD
Mianserin—Anaemia—Ezetimibe—atherosclerosis	0.000678	0.00603	CcSEcCtD
Mianserin—Tinnitus—Pravastatin—atherosclerosis	0.000677	0.00603	CcSEcCtD
Mianserin—Cardiac disorder—Pravastatin—atherosclerosis	0.000674	0.006	CcSEcCtD
Mianserin—Vertigo—Lovastatin—atherosclerosis	0.000672	0.00598	CcSEcCtD
Mianserin—Angiopathy—Niacin—atherosclerosis	0.000669	0.00596	CcSEcCtD
Mianserin—Leukopenia—Lovastatin—atherosclerosis	0.000669	0.00596	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000656	0.00584	CcSEcCtD
Mianserin—Tremor—Simvastatin—atherosclerosis	0.000655	0.00583	CcSEcCtD
Mianserin—Paraesthesia—Rosuvastatin—atherosclerosis	0.000646	0.00575	CcSEcCtD
Mianserin—Anaemia—Simvastatin—atherosclerosis	0.000646	0.00575	CcSEcCtD
Mianserin—Myalgia—Lovastatin—atherosclerosis	0.000636	0.00566	CcSEcCtD
Mianserin—Arthralgia—Lovastatin—atherosclerosis	0.000636	0.00566	CcSEcCtD
Mianserin—Hypertension—Ezetimibe—atherosclerosis	0.000633	0.00563	CcSEcCtD
Mianserin—Vertigo—Simvastatin—atherosclerosis	0.000628	0.00559	CcSEcCtD
Mianserin—Leukopenia—Simvastatin—atherosclerosis	0.000626	0.00557	CcSEcCtD
Mianserin—Arthralgia—Ezetimibe—atherosclerosis	0.000624	0.00556	CcSEcCtD
Mianserin—Myalgia—Ezetimibe—atherosclerosis	0.000624	0.00556	CcSEcCtD
Mianserin—Dry mouth—Lovastatin—atherosclerosis	0.000622	0.00554	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00062	0.00552	CcSEcCtD
Mianserin—Constipation—Rosuvastatin—atherosclerosis	0.000616	0.00548	CcSEcCtD
Mianserin—Confusional state—Lovastatin—atherosclerosis	0.000615	0.00548	CcSEcCtD
Mianserin—Dry mouth—Ezetimibe—atherosclerosis	0.00061	0.00543	CcSEcCtD
Mianserin—Confusional state—Ezetimibe—atherosclerosis	0.000603	0.00537	CcSEcCtD
Mianserin—Thrombocytopenia—Lovastatin—atherosclerosis	0.000597	0.00532	CcSEcCtD
Mianserin—HTR2A—endothelium—atherosclerosis	0.000596	0.0239	CbGeAlD
Mianserin—Myalgia—Simvastatin—atherosclerosis	0.000595	0.0053	CcSEcCtD
Mianserin—Arthralgia—Simvastatin—atherosclerosis	0.000595	0.0053	CcSEcCtD
Mianserin—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000593	0.00528	CcSEcCtD
Mianserin—Tremor—Pravastatin—atherosclerosis	0.000592	0.00527	CcSEcCtD
Mianserin—Nervous system disorder—Ezetimibe—atherosclerosis	0.000587	0.00522	CcSEcCtD
Mianserin—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000586	0.00521	CcSEcCtD
Mianserin—Anaemia—Pravastatin—atherosclerosis	0.000584	0.0052	CcSEcCtD
Mianserin—Skin disorder—Ezetimibe—atherosclerosis	0.000581	0.00517	CcSEcCtD
Mianserin—Vertigo—Niacin—atherosclerosis	0.000577	0.00513	CcSEcCtD
Mianserin—Syncope—Niacin—atherosclerosis	0.000576	0.00512	CcSEcCtD
Mianserin—Confusional state—Simvastatin—atherosclerosis	0.000575	0.00512	CcSEcCtD
Mianserin—Leukopenia—Niacin—atherosclerosis	0.000575	0.00512	CcSEcCtD
Mianserin—Oedema—Simvastatin—atherosclerosis	0.000571	0.00508	CcSEcCtD
Mianserin—Vertigo—Pravastatin—atherosclerosis	0.000568	0.00506	CcSEcCtD
Mianserin—HTR1D—connective tissue—atherosclerosis	0.000568	0.0227	CbGeAlD
Mianserin—Leukopenia—Pravastatin—atherosclerosis	0.000566	0.00504	CcSEcCtD
Mianserin—Loss of consciousness—Niacin—atherosclerosis	0.000564	0.00502	CcSEcCtD
Mianserin—Thrombocytopenia—Simvastatin—atherosclerosis	0.000559	0.00497	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000556	0.00495	CcSEcCtD
Mianserin—Diphenylpyraline—HRH1—atherosclerosis	0.000551	0.0756	CrCbGaD
Mianserin—HTR2A—blood vessel—atherosclerosis	0.00055	0.022	CbGeAlD
Mianserin—Paraesthesia—Lovastatin—atherosclerosis	0.000548	0.00488	CcSEcCtD
Mianserin—Arthralgia—Niacin—atherosclerosis	0.000547	0.00487	CcSEcCtD
Mianserin—Myalgia—Niacin—atherosclerosis	0.000547	0.00487	CcSEcCtD
Mianserin—Hypertension—Pravastatin—atherosclerosis	0.000546	0.00486	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000545	0.00485	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000543	0.00483	CcSEcCtD
Mianserin—Arthralgia—Pravastatin—atherosclerosis	0.000538	0.00479	CcSEcCtD
Mianserin—Myalgia—Pravastatin—atherosclerosis	0.000538	0.00479	CcSEcCtD
Mianserin—Paraesthesia—Ezetimibe—atherosclerosis	0.000537	0.00478	CcSEcCtD
Mianserin—Dry mouth—Niacin—atherosclerosis	0.000535	0.00476	CcSEcCtD
Mianserin—Fatigue—Lovastatin—atherosclerosis	0.000526	0.00468	CcSEcCtD
Mianserin—Oedema—Niacin—atherosclerosis	0.000524	0.00466	CcSEcCtD
Mianserin—Constipation—Lovastatin—atherosclerosis	0.000522	0.00464	CcSEcCtD
Mianserin—Confusional state—Pravastatin—atherosclerosis	0.00052	0.00463	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00052	0.00463	CcSEcCtD
Mianserin—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000517	0.0046	CcSEcCtD
Mianserin—Asthenia—Rosuvastatin—atherosclerosis	0.000517	0.0046	CcSEcCtD
Mianserin—Oedema—Pravastatin—atherosclerosis	0.000516	0.00459	CcSEcCtD
Mianserin—Fatigue—Ezetimibe—atherosclerosis	0.000516	0.00459	CcSEcCtD
Mianserin—Shock—Niacin—atherosclerosis	0.000516	0.00459	CcSEcCtD
Mianserin—Paraesthesia—Simvastatin—atherosclerosis	0.000512	0.00456	CcSEcCtD
Mianserin—Constipation—Ezetimibe—atherosclerosis	0.000512	0.00455	CcSEcCtD
Mianserin—Tachycardia—Niacin—atherosclerosis	0.000511	0.00455	CcSEcCtD
Mianserin—Pruritus—Rosuvastatin—atherosclerosis	0.000509	0.00453	CcSEcCtD
Mianserin—Skin disorder—Niacin—atherosclerosis	0.000509	0.00453	CcSEcCtD
Mianserin—Thrombocytopenia—Pravastatin—atherosclerosis	0.000505	0.0045	CcSEcCtD
Mianserin—Feeling abnormal—Lovastatin—atherosclerosis	0.000503	0.00447	CcSEcCtD
Mianserin—HTR1D—cardiovascular system—atherosclerosis	0.000494	0.0198	CbGeAlD
Mianserin—Feeling abnormal—Ezetimibe—atherosclerosis	0.000493	0.00439	CcSEcCtD
Mianserin—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000493	0.00439	CcSEcCtD
Mianserin—Fatigue—Simvastatin—atherosclerosis	0.000492	0.00438	CcSEcCtD
Mianserin—Hypotension—Niacin—atherosclerosis	0.00049	0.00436	CcSEcCtD
Mianserin—Constipation—Simvastatin—atherosclerosis	0.000488	0.00434	CcSEcCtD
Mianserin—HRH2—liver—atherosclerosis	0.000479	0.0192	CbGeAlD
Mianserin—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000477	0.00425	CcSEcCtD
Mianserin—Dizziness—Rosuvastatin—atherosclerosis	0.000476	0.00424	CcSEcCtD
Mianserin—Paraesthesia—Niacin—atherosclerosis	0.000471	0.00419	CcSEcCtD
Mianserin—Feeling abnormal—Simvastatin—atherosclerosis	0.00047	0.00419	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00047	0.00418	CcSEcCtD
Mianserin—Somnolence—Niacin—atherosclerosis	0.000466	0.00415	CcSEcCtD
Mianserin—Paraesthesia—Pravastatin—atherosclerosis	0.000463	0.00412	CcSEcCtD
Mianserin—HTR2B—cardiovascular system—atherosclerosis	0.00046	0.0184	CbGeAlD
Mianserin—Epinastine—HRH1—atherosclerosis	0.000455	0.0624	CrCbGaD
Mianserin—Rash—Rosuvastatin—atherosclerosis	0.000454	0.00404	CcSEcCtD
Mianserin—Dermatitis—Rosuvastatin—atherosclerosis	0.000453	0.00404	CcSEcCtD
Mianserin—Gastrointestinal disorder—Niacin—atherosclerosis	0.000452	0.00403	CcSEcCtD
Mianserin—HTR7—connective tissue—atherosclerosis	0.000452	0.0181	CbGeAlD
Mianserin—Headache—Rosuvastatin—atherosclerosis	0.000451	0.00401	CcSEcCtD
Mianserin—Fatigue—Pravastatin—atherosclerosis	0.000445	0.00396	CcSEcCtD
Mianserin—Cyclizine—HRH1—atherosclerosis	0.000444	0.0609	CrCbGaD
Mianserin—Constipation—Pravastatin—atherosclerosis	0.000441	0.00393	CcSEcCtD
Mianserin—Asthenia—Lovastatin—atherosclerosis	0.000438	0.0039	CcSEcCtD
Mianserin—Pruritus—Lovastatin—atherosclerosis	0.000432	0.00384	CcSEcCtD
Mianserin—Asthenia—Ezetimibe—atherosclerosis	0.000429	0.00382	CcSEcCtD
Mianserin—Mequitazine—HRH1—atherosclerosis	0.000428	0.0587	CrCbGaD
Mianserin—Feeling abnormal—Pravastatin—atherosclerosis	0.000425	0.00378	CcSEcCtD
Mianserin—Pruritus—Ezetimibe—atherosclerosis	0.000423	0.00377	CcSEcCtD
Mianserin—HTR1A—cardiovascular system—atherosclerosis	0.000412	0.0165	CbGeAlD
Mianserin—Asthenia—Simvastatin—atherosclerosis	0.000409	0.00364	CcSEcCtD
Mianserin—HTR2B—adipose tissue—atherosclerosis	0.000405	0.0162	CbGeAlD
Mianserin—Pruritus—Simvastatin—atherosclerosis	0.000404	0.00359	CcSEcCtD
Mianserin—Dizziness—Lovastatin—atherosclerosis	0.000403	0.00359	CcSEcCtD
Mianserin—Dizziness—Ezetimibe—atherosclerosis	0.000396	0.00352	CcSEcCtD
Mianserin—HTR7—cardiovascular system—atherosclerosis	0.000394	0.0158	CbGeAlD
Mianserin—Rash—Lovastatin—atherosclerosis	0.000385	0.00342	CcSEcCtD
Mianserin—Dermatitis—Lovastatin—atherosclerosis	0.000384	0.00342	CcSEcCtD
Mianserin—Headache—Lovastatin—atherosclerosis	0.000382	0.0034	CcSEcCtD
Mianserin—Dizziness—Simvastatin—atherosclerosis	0.000377	0.00336	CcSEcCtD
Mianserin—Rash—Ezetimibe—atherosclerosis	0.000377	0.00336	CcSEcCtD
Mianserin—Dermatitis—Ezetimibe—atherosclerosis	0.000377	0.00336	CcSEcCtD
Mianserin—Asthenia—Niacin—atherosclerosis	0.000376	0.00335	CcSEcCtD
Mianserin—Headache—Ezetimibe—atherosclerosis	0.000375	0.00334	CcSEcCtD
Mianserin—Pruritus—Niacin—atherosclerosis	0.000371	0.0033	CcSEcCtD
Mianserin—Asthenia—Pravastatin—atherosclerosis	0.00037	0.00329	CcSEcCtD
Mianserin—Pruritus—Pravastatin—atherosclerosis	0.000365	0.00325	CcSEcCtD
Mianserin—Rash—Simvastatin—atherosclerosis	0.00036	0.0032	CcSEcCtD
Mianserin—Dermatitis—Simvastatin—atherosclerosis	0.000359	0.0032	CcSEcCtD
Mianserin—Mirtazapine—HRH1—atherosclerosis	0.000358	0.0491	CrCbGaD
Mianserin—Headache—Simvastatin—atherosclerosis	0.000358	0.00318	CcSEcCtD
Mianserin—Cyproheptadine—HRH1—atherosclerosis	0.000347	0.0476	CrCbGaD
Mianserin—Dizziness—Niacin—atherosclerosis	0.000347	0.00308	CcSEcCtD
Mianserin—Dizziness—Pravastatin—atherosclerosis	0.000341	0.00304	CcSEcCtD
Mianserin—HRH1—connective tissue—atherosclerosis	0.000338	0.0135	CbGeAlD
Mianserin—ADRA2A—connective tissue—atherosclerosis	0.000332	0.0133	CbGeAlD
Mianserin—Rash—Niacin—atherosclerosis	0.00033	0.00294	CcSEcCtD
Mianserin—Dermatitis—Niacin—atherosclerosis	0.00033	0.00294	CcSEcCtD
Mianserin—Headache—Niacin—atherosclerosis	0.000328	0.00292	CcSEcCtD
Mianserin—Rash—Pravastatin—atherosclerosis	0.000325	0.0029	CcSEcCtD
Mianserin—Dermatitis—Pravastatin—atherosclerosis	0.000325	0.00289	CcSEcCtD
Mianserin—Headache—Pravastatin—atherosclerosis	0.000323	0.00288	CcSEcCtD
Mianserin—ADRA2C—adipose tissue—atherosclerosis	0.000319	0.0128	CbGeAlD
Mianserin—CYP2B6—cardiovascular system—atherosclerosis	0.000301	0.0121	CbGeAlD
Mianserin—Prochlorperazine—HRH1—atherosclerosis	0.000291	0.0399	CrCbGaD
Mianserin—HTR2A—connective tissue—atherosclerosis	0.000282	0.0113	CbGeAlD
Mianserin—HRH1—adipose tissue—atherosclerosis	0.000259	0.0104	CbGeAlD
Mianserin—ADRA2A—adipose tissue—atherosclerosis	0.000255	0.0102	CbGeAlD
Mianserin—HTR2A—cardiovascular system—atherosclerosis	0.000245	0.00983	CbGeAlD
Mianserin—HTR7—liver—atherosclerosis	0.000243	0.00975	CbGeAlD
Mianserin—Nortriptyline—HRH1—atherosclerosis	0.000235	0.0323	CrCbGaD
Mianserin—ADRA2C—liver—atherosclerosis	0.000224	0.00896	CbGeAlD
Mianserin—Trimipramine—HRH1—atherosclerosis	0.000221	0.0304	CrCbGaD
Mianserin—CYP1A2—liver—atherosclerosis	0.000194	0.00778	CbGeAlD
Mianserin—Desipramine—HRH1—atherosclerosis	0.000194	0.0266	CrCbGaD
Mianserin—CYP2B6—liver—atherosclerosis	0.000186	0.00745	CbGeAlD
Mianserin—Imipramine—HRH1—atherosclerosis	0.000164	0.0225	CrCbGaD
Mianserin—Amitriptyline—HRH1—atherosclerosis	0.000163	0.0224	CrCbGaD
Mianserin—HTR2A—liver—atherosclerosis	0.000152	0.00608	CbGeAlD
Mianserin—CYP3A4—liver—atherosclerosis	0.00014	0.00563	CbGeAlD
Mianserin—CYP2D6—liver—atherosclerosis	0.000138	0.00554	CbGeAlD
Mianserin—Oxcarbazepine—ALB—atherosclerosis	9.68e-05	0.0133	CrCbGaD
Mianserin—Nortriptyline—ALB—atherosclerosis	5.43e-05	0.00745	CrCbGaD
Mianserin—Amitriptyline—ALB—atherosclerosis	3.77e-05	0.00517	CrCbGaD
Mianserin—CYP2B6—Metabolism—INS—atherosclerosis	4.18e-06	3.04e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	4.17e-06	3.03e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—INS—atherosclerosis	4.17e-06	3.03e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NOS3—atherosclerosis	4.16e-06	3.02e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	4.15e-06	3.01e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NOS3—atherosclerosis	4.14e-06	3.01e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	4.14e-06	3.01e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—GSTM1—atherosclerosis	4.14e-06	3e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MMP9—atherosclerosis	4.12e-06	2.99e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—F2—atherosclerosis	4.12e-06	2.99e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—VEGFA—atherosclerosis	4.11e-06	2.99e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—INS—atherosclerosis	4.1e-06	2.98e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCL2—atherosclerosis	4.1e-06	2.98e-05	CbGpPWpGaD
Mianserin—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	4.09e-06	2.97e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—INS—atherosclerosis	4.09e-06	2.97e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—ALB—atherosclerosis	4.09e-06	2.97e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	4.08e-06	2.96e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—STAT3—atherosclerosis	4.07e-06	2.96e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—LPL—atherosclerosis	4.06e-06	2.95e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—VEGFA—atherosclerosis	4.05e-06	2.94e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—VEGFA—atherosclerosis	4.05e-06	2.94e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCL2—atherosclerosis	4.04e-06	2.93e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IGF1—atherosclerosis	4.03e-06	2.93e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—IL6—atherosclerosis	4.03e-06	2.93e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	4.03e-06	2.92e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCL2—atherosclerosis	4.03e-06	2.92e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	4.02e-06	2.92e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.02e-06	2.92e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—STAT3—atherosclerosis	4.01e-06	2.91e-05	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—AKT1—atherosclerosis	4.01e-06	2.91e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—STAT3—atherosclerosis	4.01e-06	2.91e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	4.01e-06	2.91e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	4e-06	2.9e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—STAT3—atherosclerosis	3.98e-06	2.89e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IGF1—atherosclerosis	3.97e-06	2.88e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—GPX1—atherosclerosis	3.96e-06	2.88e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IGF1—atherosclerosis	3.96e-06	2.87e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	3.94e-06	2.86e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—NOS3—atherosclerosis	3.91e-06	2.84e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—MAPK3—atherosclerosis	3.89e-06	2.82e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CD36—atherosclerosis	3.86e-06	2.8e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—ALB—atherosclerosis	3.84e-06	2.78e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—MAPK3—atherosclerosis	3.83e-06	2.78e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MMP9—atherosclerosis	3.83e-06	2.78e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—MAPK3—atherosclerosis	3.83e-06	2.78e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	3.83e-06	2.78e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	3.83e-06	2.78e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	3.8e-06	2.76e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.8e-06	2.76e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—NFKB1—atherosclerosis	3.79e-06	2.75e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	3.78e-06	2.74e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	3.77e-06	2.74e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.77e-06	2.74e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—HMOX1—atherosclerosis	3.76e-06	2.73e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.76e-06	2.73e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—INS—atherosclerosis	3.73e-06	2.71e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK8—atherosclerosis	3.73e-06	2.71e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TGFB1—atherosclerosis	3.72e-06	2.7e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—AKT1—atherosclerosis	3.72e-06	2.7e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TGFB1—atherosclerosis	3.72e-06	2.7e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	3.7e-06	2.69e-05	CbGpPWpGaD
Mianserin—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	3.7e-06	2.68e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.69e-06	2.68e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	3.69e-06	2.68e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.67e-06	2.67e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	3.67e-06	2.67e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—NOS3—atherosclerosis	3.67e-06	2.66e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—STAT3—atherosclerosis	3.66e-06	2.66e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—MTHFR—atherosclerosis	3.66e-06	2.65e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NOS3—atherosclerosis	3.66e-06	2.65e-05	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—IL6—atherosclerosis	3.65e-06	2.65e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	3.64e-06	2.64e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	3.61e-06	2.62e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—APOB—atherosclerosis	3.6e-06	2.62e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.6e-06	2.61e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.59e-06	2.61e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PPARA—atherosclerosis	3.59e-06	2.6e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTGS2—atherosclerosis	3.58e-06	2.6e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	3.57e-06	2.59e-05	CbGpPWpGaD
Mianserin—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.57e-06	2.59e-05	CbGpPWpGaD
Mianserin—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.55e-06	2.58e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.51e-06	2.55e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—GSTM1—atherosclerosis	3.5e-06	2.54e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	3.5e-06	2.54e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—IL6—atherosclerosis	3.49e-06	2.54e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—AGT—atherosclerosis	3.47e-06	2.52e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	3.46e-06	2.51e-05	CbGpPWpGaD
Mianserin—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	3.45e-06	2.51e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—VEGFA—atherosclerosis	3.44e-06	2.5e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—LPL—atherosclerosis	3.44e-06	2.5e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	3.43e-06	2.49e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	3.42e-06	2.49e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—STAT3—atherosclerosis	3.41e-06	2.47e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—APOE—atherosclerosis	3.4e-06	2.47e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	3.4e-06	2.47e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	3.4e-06	2.46e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.38e-06	2.46e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CAV1—atherosclerosis	3.37e-06	2.45e-05	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—AKT1—atherosclerosis	3.37e-06	2.45e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	3.37e-06	2.44e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—APOA1—atherosclerosis	3.37e-06	2.44e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—GPX1—atherosclerosis	3.36e-06	2.44e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	3.36e-06	2.44e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTGS2—atherosclerosis	3.36e-06	2.44e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MMP9—atherosclerosis	3.34e-06	2.43e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MMP9—atherosclerosis	3.32e-06	2.41e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	3.31e-06	2.4e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	3.29e-06	2.39e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	3.27e-06	2.38e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CD36—atherosclerosis	3.27e-06	2.37e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK3—atherosclerosis	3.26e-06	2.36e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	3.25e-06	2.36e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CXCL8—atherosclerosis	3.24e-06	2.35e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	3.24e-06	2.35e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	3.23e-06	2.35e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	3.23e-06	2.35e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	3.22e-06	2.34e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	3.2e-06	2.32e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	3.19e-06	2.32e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.18e-06	2.31e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TGFB1—atherosclerosis	3.16e-06	2.29e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	3.14e-06	2.28e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	3.14e-06	2.28e-05	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	3.13e-06	2.27e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	3.11e-06	2.26e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.1e-06	2.25e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—IL6—atherosclerosis	3.08e-06	2.24e-05	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	3.08e-06	2.24e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	3.08e-06	2.23e-05	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.08e-06	2.23e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.07e-06	2.23e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PPARA—atherosclerosis	3.04e-06	2.21e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—IL6—atherosclerosis	3.03e-06	2.2e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—IL6—atherosclerosis	3.03e-06	2.2e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	3e-06	2.18e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.98e-06	2.17e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.97e-06	2.16e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PPARG—atherosclerosis	2.97e-06	2.15e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.95e-06	2.15e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—AGT—atherosclerosis	2.94e-06	2.14e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	2.94e-06	2.13e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MMP9—atherosclerosis	2.93e-06	2.13e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—INS—atherosclerosis	2.91e-06	2.11e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.9e-06	2.11e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	2.9e-06	2.11e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	2.9e-06	2.11e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NFKB1—atherosclerosis	2.9e-06	2.11e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.89e-06	2.1e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—APOE—atherosclerosis	2.88e-06	2.09e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.88e-06	2.09e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	2.87e-06	2.09e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CAV1—atherosclerosis	2.86e-06	2.07e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.86e-06	2.07e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.85e-06	2.07e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	2.85e-06	2.07e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—APOA1—atherosclerosis	2.85e-06	2.07e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.85e-06	2.07e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.84e-06	2.07e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—IL6—atherosclerosis	2.84e-06	2.06e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.84e-06	2.06e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.82e-06	2.05e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.81e-06	2.04e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.8e-06	2.04e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—IL6—atherosclerosis	2.8e-06	2.03e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.8e-06	2.03e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—IL6—atherosclerosis	2.8e-06	2.03e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.8e-06	2.03e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.79e-06	2.03e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.78e-06	2.02e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—APOB—atherosclerosis	2.78e-06	2.02e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.76e-06	2e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.75e-06	2e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	2.75e-06	1.99e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.74e-06	1.99e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.7e-06	1.96e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—ALB—atherosclerosis	2.67e-06	1.94e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	2.66e-06	1.93e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—LPL—atherosclerosis	2.66e-06	1.93e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—VEGFA—atherosclerosis	2.63e-06	1.91e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	2.63e-06	1.91e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—AKT1—atherosclerosis	2.62e-06	1.9e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—STAT3—atherosclerosis	2.61e-06	1.89e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CG—atherosclerosis	2.6e-06	1.89e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	2.6e-06	1.89e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.59e-06	1.88e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GPX1—atherosclerosis	2.59e-06	1.88e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.59e-06	1.88e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—AKT1—atherosclerosis	2.59e-06	1.88e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—AKT1—atherosclerosis	2.58e-06	1.87e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—AKT1—atherosclerosis	2.57e-06	1.86e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.57e-06	1.86e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.56e-06	1.86e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—IL6—atherosclerosis	2.56e-06	1.86e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	2.55e-06	1.85e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—NOS3—atherosclerosis	2.55e-06	1.85e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	2.55e-06	1.85e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CD36—atherosclerosis	2.52e-06	1.83e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PPARG—atherosclerosis	2.51e-06	1.82e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK3—atherosclerosis	2.49e-06	1.81e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—INS—atherosclerosis	2.46e-06	1.79e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.45e-06	1.78e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.45e-06	1.78e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TGFB1—atherosclerosis	2.42e-06	1.75e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.39e-06	1.74e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL6—atherosclerosis	2.38e-06	1.73e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.38e-06	1.73e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.37e-06	1.72e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—AKT1—atherosclerosis	2.36e-06	1.71e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	2.36e-06	1.71e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PPARA—atherosclerosis	2.35e-06	1.7e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	2.33e-06	1.69e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.33e-06	1.69e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—AGT—atherosclerosis	2.27e-06	1.65e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ALB—atherosclerosis	2.26e-06	1.64e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	2.23e-06	1.62e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—APOE—atherosclerosis	2.23e-06	1.62e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—AKT1—atherosclerosis	2.21e-06	1.61e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CAV1—atherosclerosis	2.21e-06	1.6e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—APOA1—atherosclerosis	2.2e-06	1.6e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—AKT1—atherosclerosis	2.2e-06	1.59e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.16e-06	1.57e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—NOS3—atherosclerosis	2.16e-06	1.57e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL6—atherosclerosis	2.15e-06	1.56e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL6—atherosclerosis	2.07e-06	1.51e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.06e-06	1.5e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.01e-06	1.46e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL6—atherosclerosis	2.01e-06	1.46e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	1.98e-06	1.44e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.98e-06	1.43e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PPARG—atherosclerosis	1.94e-06	1.41e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.91e-06	1.39e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.9e-06	1.38e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—INS—atherosclerosis	1.9e-06	1.38e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.85e-06	1.34e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL6—atherosclerosis	1.82e-06	1.32e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—AKT1—atherosclerosis	1.8e-06	1.31e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.79e-06	1.3e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL6—atherosclerosis	1.79e-06	1.3e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ALB—atherosclerosis	1.74e-06	1.27e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—AKT1—atherosclerosis	1.69e-06	1.22e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.68e-06	1.22e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—NOS3—atherosclerosis	1.67e-06	1.21e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.65e-06	1.2e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.65e-06	1.2e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.63e-06	1.18e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.52e-06	1.11e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.5e-06	1.09e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—AKT1—atherosclerosis	1.17e-06	8.51e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—AKT1—atherosclerosis	9.93e-07	7.21e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—AKT1—atherosclerosis	7.66e-07	5.56e-06	CbGpPWpGaD
